RaySearch Laboratories AB (publ)
RSLBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7 | $3 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $7 | $3 | $2 | $2 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 16.6% | 21.2% | 31.5% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 91.7% | 89.6% | 88.7% | 92.1% |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 47.9% | 39.7% | 40.4% | 30.8% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 17.1% | 8% | 2.8% | -7.4% |
| EPS Diluted | 5.94 | 2.38 | 0.69 | -1.38 |
| % Growth | 149.6% | 244.9% | 150% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | -$0 |